Bosentan therapy for pulmonary arterial hypertension

New England Journal of Medicine

Volumn 346, Issue 12, 2002, Pages 896-903

  Rubin, Lewis J ^a   Badesch, David B ^b   Barst, Robyn J ^c   Galiè, Nazzareno ^d   Black, Carol M ^e   Keogh, Anne ^f   Pulido, Tomas ^g   Frost, Adaani ^h   Roux, Sébastien ⁱ   Leconte, Isabelle ⁱ   Landzberg, Michael ^j   Simonneau, Gérald ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f ST VINCENT S HOSPITAL   (Australia)

^g INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ ACTELION PHARMACEUTICALS LTD   (Switzerland)

^j HARVARD MEDICAL SCHOOL   (United States)

^k HÔPITAL ANTOINE BÉCLÈRE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; EXERCISE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0037149718     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012212     Document Type: Article

References (21)

1. Primary pulmonary hypertension
2. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis
3. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
4. Primary pulmonary hypertension: Natural history and the importance of thrombosis
5. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
6. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group
7. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
8. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
9. Orally active prostacyclin analogue in primary pulmonary hypertension
10. Endothelin-1: A mediator of pulmonary hypertension?
11. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
12. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension
13. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
14. Endothelin and collagen vascular disease: A review with special reference to Raynaud's phenomenon and systemic sclerosis
15. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
16. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
17. Psychophysical bases of perceived exertion
18. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: Comparison with cardiopulmonary exercise testing
19. Update of REACH-1 and MERIT-HF clinical trials in heart failure
20. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure